|1.||Fukuda, Satoshi: 2 articles (07/2005 - 01/2005)|
|2.||Xie, Yuyuan: 1 article (07/2005)|
|3.||Yan, Xueming: 1 article (07/2005)|
|4.||Iida, Haruzo: 1 article (07/2005)|
|5.||Ikeda, Mizuyo: 1 article (07/2005)|
|6.||Houpert, P: 1 article (02/2004)|
|7.||Paquet, F: 1 article (02/2004)|
|8.||Chazel, V: 1 article (02/2004)|
|1.||Wounds and Injuries (Trauma)
07/01/2005 - "We examined the acute toxicity of uranium (99.3% 238U, 0.7% 235U) and the effects of Catechol-3,6-bis(methyleiminodiacetic acid) (CBMIDA) and Ethane-1-hydroxy-1,1-bisphosphonate (EHBP) on the removal of uranium after intramuscular injection as a simulated wound intake in rats. "
02/01/2004 - "A wound dressing and a paste mixed or not with uranium-chelating ligands, ethane-1-hydroxy-1,1-bisphosphonate (EHBP) and carballylic amido bis phosphonic acid (CAPBP), were tested in vitro on muscles and in vivo on rats after deposit of uranium oxide compounds. "
01/01/2005 - "Recently, the focus has turned to drugs that have been used successfully in the treatment of a variety of other diseases, for example the iron chelating drug deferiprone or 1,2-dimethyl-3-hydroxypyrid-4-one (L1), which is used in thalassaemia and ethane-1-hydroxy-1,1-bisphosphonate (EHBP), which is used in osteoporosis. "
|5.||uranium oxide (uranium trioxide)